

**Supplementary Table S3. Reduction of plasma ApoAII-2 and ApoCIII-0 in patients with pancreatic cancer (Cohorts 1 and 2)**

	Cohort 1 ( <i>n</i> = 215)					Cohort 2 ( <i>n</i> = 103)				
	Healthy control	Pancreatic cancer		AUC	95% CI <sup>b</sup>	Healthy control	Pancreatic cancer		AUC	95% CI <sup>b</sup>
	Mean ± SD ( <i>n</i> = 112)	Mean ± SD ( <i>n</i> = 103)	<i>P</i> -value <sup>a</sup>			Mean ± SD ( <i>n</i> = 41)	Mean ± SD ( <i>n</i> = 62)	<i>P</i> -value <sup>a</sup>		
ApoAII-3	95.5 ± 32.4	62.4 ± 32.6	1.48E-12	0.780	(0.716-0.843)	98.1 ± 30.1	58.1 ± 34.2	8.23E-09	0.837	(0.758-0.961)
<b>ApoAII-2</b>	235.3 ± 38.0	165.2 ± 49.8	1.36E-21	<b>0.877</b>	(0.832-0.922)	237.5 ± 44.2	157.9 ± 54.8	9.72E-11	<b>0.878</b>	(0.812-0.944)
<b>ApoAII-2ox</b>	79.0 ± 9.8	63.6 ± 11.1	5.14E-20	<b>0.862</b>	(0.812-0.911)	80.1 ± 11.4	61.9 ± 13.5	2.43E-09	<b>0.849</b>	(0.774-0.923)
ApoAII-1	212.6 ± 73.0	255.3 ± 116.5	3.55E-03	0.615	(0.537-0.963)	207.5 ± 69.9	244.3 ± 100.3	1.21E-02	0.647	(0.539-0.755)
<b>ApoCIII-0</b>	105.6 ± 24.1	80.9 ± 24.1	4.35E-14	<b>0.798</b>	(0.738-0.859)	112.0 ± 27.9	72.7 ± 22.5	1.31E-11	<b>0.895</b>	(0.837-0.954)
ApoCIII-1	169.0 ± 29.2	147.9 ± 30.9	1.37E-06	0.691	(0.620-0.761)	180.8 ± 31.4	139.4 ± 39.3	1.21E-07	0.809	(0.728-0.890)
ApoCIII-2	56.1 ± 7.16	55.9 ± 8.78	6.43E-01	0.518	(0.441-0.596)	59.3 ± 7.31	54.5 ± 9.72	9.58E-03	0.651	(0.547-0.756)
ApoAI	177.2 ± 21.3	166.7 ± 27.2	9.10E-03	0.603	(0.528-0.679)	191.7 ± 27.6	173.3 ± 36.3	1.76E-02	0.639	(0.531-0.747)
<b>ApoAII-2+CIII-0</b>	340.9 ± 49.3	246.0 ± 55.5	1.83E-24	<b>0.903</b>	(0.863-0.944)	349.5 ± 57.7	230.6 ± 68.3	2.88E-13	<b>0.926</b>	(0.876-0.977)

<sup>a</sup>Calculated by Mann-Whitney U-test. AUC values larger than 0.8 are highlighted in boldface.